Increase in antibody titer and change over time associated with severe acute respiratory syndrome coronavirus 2 infection after mRNA vaccination: Consideration of the significance of additional vaccination

被引:2
作者
Kusunoki, Hiroshi [1 ]
Ohkusa, Michiko [2 ]
Iida, Rie [2 ]
Saito, Ayumi [2 ]
Kawahara, Mikio [2 ]
Ekawa, Kazumi [1 ,3 ]
Kato, Nozomi [1 ]
Motone, Masaharu [1 ,4 ]
Shimizu, Hideo [1 ]
机构
[1] Osaka Dent Univ, Dept Internal Med, 8-1 Kuzuhahanazonocho, Hirakata, Osaka 5731121, Japan
[2] Osaka Dent Univ Hosp, Dept Lab Med, Osaka, Japan
[3] Hyogo Med Univ, Dept Environm & Prevent Med, Nishinomiya, Japan
[4] Osaka Dent Univ, Fac Hlth Sci, Hirakata, Japan
来源
CLINICAL CASE REPORTS | 2024年 / 12卷 / 06期
关键词
breakthrough infection; COVID-19; SARS-CoV-2; antibody; vaccines;
D O I
10.1002/ccr3.8953
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Spontaneous infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after mRNA vaccination causes a marked increase in antibody titer because of the combined effect of vaccine and infection ("hybrid immunity"). In this study, we discuss the significance of the mRNA vaccine booster inoculation that has been repeatedly performed in Japan. We describe the temporal trends of antibody titers in cases in which antibody titers were markedly increased by hybrid immunization. The antibody titer increased with hybrid immunization and tended to decrease with time. However, several cases maintained high antibody titers for approximately 1 year after coronavirus disease 2019 (COVID-19) diagnosis, even without booster vaccination. Most Japanese patients naturally infected with COVID-19 were infected after mRNA vaccination, and many maintained high antibody titers due to hybrid immunity. The significance of additional vaccination in hybrid-immunized cases is highly questionable regarding cost-effectiveness and risk-benefit.
引用
收藏
页数:8
相关论文
共 30 条
  • [11] kantei, About us.
  • [12] Evaluating the COVID-19 vaccination program in Japan, 2021 using the counterfactual reproduction number
    Kayano, Taishi
    Ko, Yura
    Otani, Kanako
    Kobayashi, Tetsuro
    Suzuki, Motoi
    Nishiura, Hiroshi
    [J]. SCIENTIFIC REPORTS, 2023, 13 (01)
  • [13] Konishi N., 2024, Rinsho Hyoka(Clinical Evaluation), V51, P479
  • [14] kuraraynoritake, about us
  • [15] Kusunoki H., 2023, Pharmacoepidemiology, V2, P188, DOI [10.3390/pharma2030017, DOI 10.3390/PHARMA2030017]
  • [16] Longitudinal Changes in IgG-Type SARS-CoV-2 Antibody Titers after COVID-19 Vaccination and a Prominent Increase in Antibody Titers When Infected after Vaccination
    Kusunoki, Hiroshi
    Ohkusa, Michiko
    Iida, Rie
    Saito, Ayumi
    Kawahara, Mikio
    Ekawa, Kazumi
    Kato, Nozomi
    Yamasaki, Keita
    Motone, Masaharu
    Shimizu, Hideo
    [J]. VACCINES, 2023, 11 (04)
  • [17] Kusunoki Hiroshi, 2023, Medicines (Basel), V10, DOI 10.3390/medicines10040027
  • [18] Longitudinal antibody dynamics after COVID-19 vaccine boosters based on prior infection status and booster doses
    Matsumoto, Naomi
    Sasaki, Ayako
    Kadowaki, Tomoka
    Mitsuhashi, Toshiharu
    Takao, Soshi
    Yorifuji, Takashi
    [J]. SCIENTIFIC REPORTS, 2024, 14 (01)
  • [19] mhlw, about us
  • [20] Memory B Cells and Memory T Cells Induced by SARS-CoV-2 Booster Vaccination or Infection Show Different Dynamics and Responsiveness to the Omicron Variant
    Mise-Omata, Setsuko
    Ikeda, Mari
    Takeshita, Masaru
    Uwamino, Yoshifum
    Wakui, Masatoshi
    Arai, Tomoko
    Yoshifuji, Ayumi
    Murano, Kensaku
    Siomi, Haruhiko
    Nakagawara, Kensuke
    Ohyagi, Masaki
    Ando, Makoto
    Hasegawa, Naoki
    Saya, Hideyuki
    Murata, Mitsuru
    Fukunaga, Koichi
    Namkoong, Ho
    Lu, Xiuyuan
    Yamasaki, Sho
    Yoshimura, Akihiko
    [J]. JOURNAL OF IMMUNOLOGY, 2022, 209 (11) : 2104 - 2113